Merck & Co., Inc. (NYSE:MRK) Shares Sold by Trust Co of Kansas

Trust Co of Kansas trimmed its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 2.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,275 shares of the company’s stock after selling 2,467 shares during the period. Merck & Co., Inc. comprises about 5.8% of Trust Co of Kansas’ holdings, making the stock its 3rd biggest position. Trust Co of Kansas’ holdings in Merck & Co., Inc. were worth $10,724,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Norges Bank purchased a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $3,108,366,000. Wellington Management Group LLP boosted its holdings in shares of Merck & Co., Inc. by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after purchasing an additional 5,196,914 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock valued at $3,966,029,000 after purchasing an additional 4,731,152 shares during the last quarter. Bank of Nova Scotia boosted its holdings in shares of Merck & Co., Inc. by 352.2% in the 4th quarter. Bank of Nova Scotia now owns 3,144,632 shares of the company’s stock valued at $342,814,000 after purchasing an additional 2,449,211 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado lifted its holdings in shares of Merck & Co., Inc. by 29,914.1% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 2,410,732 shares of the company’s stock valued at $262,818,000 after acquiring an additional 2,402,700 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $126.40 on Monday. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $134.63. The firm has a 50-day simple moving average of $129.14 and a 200 day simple moving average of $125.13. The company has a market cap of $320.15 billion, a PE ratio of 140.50, a P/E/G ratio of 2.44 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. During the same quarter in the prior year, the firm earned $1.40 EPS. Merck & Co., Inc.’s quarterly revenue was up 8.9% on a year-over-year basis. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 8.62 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 2.44%. The ex-dividend date of this dividend is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.22%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MRK shares. Berenberg Bank lifted their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Truist Financial boosted their price objective on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $133.00.

View Our Latest Stock Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.